REAL WORLD EXPERIENCE OF HIF-PHI – DESIDUSTAT (OXEMIA®) IN DIALYSIS AND NON-DIALYSIS DEPENDENT CKD ANEMIA PATIENTS

Introduction:

Chronic Kidney Disease (CKD)-induced anemia is due to  relative deficiency of erythropoietin produced by the kidneys. Recently, newer HIF-PHI – Desidustat (Oxemia®) approved in INDIA; have shown promise in correcting anemia in both dialysis-dependent and non-dialysis-dependent CKD patients. Our study presents a retrospective analysis of the usage of Desidustat in CKD Anemia Patients. 

Methods:

This retrospective analysis was conducted at Jaypee Hospital,Greater Noida. We enrolled patients CKD Anemia at our center. These subjects received treatment with Desidustat at doses of 100 mg, 125 mg, 150 mg thrice weekly, with regular monitoring of hemoglobin levels during follow-up. Subjects with ADPKD and H/O Malignancy were excluded from the study. Dose of Desidustat (Oxemia®) was modified/reduced to maintain the Hb of 11-12 gm/dl.

Results:

We enrolled a total of 35 patients, including 6 (17.1%) with CKD stage 3, 7 (20%) with CKD stage 4, 13 (37.14%) with stage 5 CKD, and 9 (25.7%) with other forms of renal impairments (Renal Cortical Necrosis, AKD, IgA Nephropathy, CIN, Obstructive Nephropathy). The mean age among the subjects was 59.13 ± 15 years. Of these, 20 (57.1%) were female and 15 (42.8%) were male. The majority (33, 94.2%) were non-dialysis-dependent, while 2 (5.7%) were dialysis-dependent. Among the patients, 16 (45.7%) had hypertension, 11 (31.4%) had diabetes, 1 (2.8) had CAD, and 1 (2.8%) had Diabetic Nephropathy. All patients received Desidustat thrice weekly on alternate days, with intravenous iron supplementation based on iron profile. The majority received Desidustat at a dose of 100 mg (n = 32, 94.2%), while one patient required 125 mg (n = 1, 2.8%) and another required 50 mg (n = 1, 2.8%). The mean serum creatinine was 3.98 ± 0.45 mg/dL, eGFR was 21.31 ± 1.67 mL/min/1.73m2. The mean baseline hemoglobin (Hb) at the start of treatment was 8.6± 1.4 g/dL, which increased to 10.3 ± 1.7 g/dL by the end of the study (p<0.05, one-way ANOVA). All patients demonstrated good compliance with Desidustat treatment. Mild adverse events were transient and self-resolved.

Conclusions:

Desidustat is a safe alternative to the Erythropoietin in CKD – Anemia treatment in Non-Dialysis dependent patients. More real-world data needed to show the efficacy in Dialysis dependent patients. 

I have no potential conflict of interest to disclose.

I did not use generative AI and AI-assisted technologies in the writing process.